Viatris Inc. has announced the appointment of Matthew J. Maletta as the new Chief Legal Officer, effective February 9, 2026. This decision comes as the company prepares for the transition of its current CLO, Brian Roman, who has dedicated over two decades of exemplary service to Viatris and its predecessor company, Mylan. Roman will remain with the company until April 1, 2026, to facilitate a seamless transition.
Maletta joins Viatris with an impressive background in the pharmaceutical sector. Over nearly 30 years, he has developed a strong legal acumen, particularly in leadership roles at both generic and branded pharmaceutical companies. Most recently, he served as Executive Vice President, Chief Legal Officer, and Corporate Secretary at Endo from 2015 to 2025. During his tenure there, he played a significant role in Endo’s merger with Mallinckrodt and the subsequent spin-off of Par Health.
Previously, Maletta spent over a decade at Allergan, advancing to roles such as Vice President, Associate General Counsel, and Corporate Secretary. His legal expertise was instrumental in major business development transactions, including the landmark $70 billion sale of Allergan to Actavis. Early in his career, he honed his legal skills as an Associate Attorney at Skadden, Arps, Slate, Meagher and Flom LLP.
In expressing gratitude toward Roman, Scott A. Smith, CEO of Viatris, stated, “On behalf of the Board of Directors and our entire company, I want to thank Brian Roman for his many years of dedicated leadership and service to our company.” Smith acknowledged Roman’s significant contributions and expressed optimism about Maletta’s arrival.
Maletta himself expressed enthusiasm about joining Viatris at this pivotal time. “This is a unique opportunity to join Viatris at an exciting time in its journey,” he remarked. “I am honored to join the company and be part of an extraordinary team that makes a real difference each and every day.”
Roman reflected on his tenure, stating, “I have had so many tremendous experiences during my more than 20 years at Mylan and Viatris. I’m proud of all that we have accomplished together.” He emphasized the importance of the company’s legal and compliance teams and looked forward to working closely with Maletta during the transition.
Viatris Inc., headquartered in the United States with global centers in Pittsburgh, Shanghai, and Hyderabad, India, aims to bridge the gap between generic and branded pharmaceuticals. The company’s mission is to empower people worldwide to live healthier lives by providing access to high-quality medicines. With a vast portfolio of products, Viatris serves approximately 1 billion patients globally each year, addressing various health challenges across all stages of life.
As Viatris moves forward under new leadership, the company remains committed to its goal of sustainable growth and advancing healthcare access worldwide.
